［1］ Proctor S J, White J, Jones G L. An international approach to the treatment of Hodgkin’s disease in the elderly: launch of the SHIELD study programme［J］. Eur J Haematol Suppl，2005, (66):63-67.

［2］ Engert A, Ballova V, Haverkamp H, et al. Hodgkin’s lymphoma in elderly patients:a comprehensive retrospective analysis from the German Hodgkin’s Study Group［J］. J Clin Oncol， 2005, 23(22): 5052-5060.

［3］ Landgren O, Algernon C, Axdorph U, et al. Hodgkin’s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis［J］. Haematologica, 2003, 88(4): 438-444.

［4］ Roy P, Vaughan Hudson G, Vaughan Hudson B, et al. Long-term survival in Hodgkin’s disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries［J］. Eur J Cancer,2000, 36(3): 384-389.

［5］ Bazzeh F, Rihani R, Howard S, et al. Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988-2005: an analysis of 21 734 cases［J］. Leuk Lymphoma,2010, 51(12): 2198-2207.

［6］ Alexander F E, Jarrett R F, Lawrence D, et al. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents［J］. Br J Cancer, 2000, 82(5):1117-1121.

［7］ Keegan T H, Glaser S L, Clarke C A, et al. Epstein-Barr virus as a marker of survival after Hodgkin’s lymphoma: a population-based study［J］. J Clin Oncol,2005, 23(30): 7604-7613.

［8］ Stark G L, Wood K M, Jack F, et al. Hodgkin’s disease in the elderly: a population-based study［J］. Br J Haematol, 2002, 119(2):432-440.

［9］ Kelley T W, Pohlman B, Elson P, et al. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression［J］. Am J Clin Pathol, 2007, 128(6): 958-965.

［10］ Mir R, Anderson J, Strauchen J, et al. Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B［J］. Cancer, 1993, 71(5): 1857-1866.

［11］ Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients［J］. Blood,2008, 111(6): 2977-2983.

［12］ Levis A, Anselmo A P, Ambrosetti A, et al. VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study［J］. Ann Oncol,2004, 15(1): 123-128.

［13］ Spronsen D J, Janssen-Heijnen M L, Lemmens V E, et al. Independent prognostic effect of co-morbidity in lymphoma patients: results of the population- based Eindhoven Cancer Registry［J］. Eur J Cancer,2005, 41(7): 1051-1057.

［14］ Evens A M, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era［J］. Blood,2012, 119(3): 692-695.

［15］ Enblad G, Gustavsson A, Sundstrom C, et al. Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy［J］. Acta Oncol,2002,41 (7-8): 659-667.

［16］ Weekes C D, Vose J M, Lynch J C, et al. Hodgkin’s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen［J］. J Clin Oncol,2002, 20(4): 1087-1093.

［17］ Boll B, Gorgen H, Fuchs M, et al. Feasibility and efficacy of ABVD in elderly Hodgkin lymphoma patients: analysis of two randomized prospective multicenter trials of the German Hodgkin Study Group (HD10 and HD11) ［J］. Blood (ASH Annual Meeting Abstracts), 2010, 116: 418.

［18］ Levis A, Depaoli L, Urgesi A, et al. Probability of cure in elderly Hodgkin’s disease patients［J］. Haematologica, 1994, 79(1): 46-54.

［19］ Levis A, Depaoli L, Bertini M, et al. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin’s disease patients［J］. Haematologica,1996, 81(5): 450-456.

［20］ Boll B, Bredenfeld H, Gorgen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma［J］. Blood. 2011, 118(24): 6292-6298.

［21］ Martin W G, Ristow K M, Habermann T M, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma［J］. J Clin Oncol,2005, 23(30): 7614-7620.

［22］ Duggan D B, Petroni G R, Johnson J L, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial［J］. J Clin Oncol,2003, 21(4): 607-614.

［23］ Fanale M A, Fayed L E, Romaguera J E, et al. Experience with R-CHOP in patients with lymphocyte predominant Hodgkin lymphoma (LPHL). 7th International Symposium on Hodgkin Lymphoma［J］. Haematologica, 2007, 92(s5): 57.

［24］ Jona A, Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma［J］. Blood,2010, 24(6): 233-238.

［25］ Kolstad A, Nome O, Delabie J, et al. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin’s lymphoma［J］. Leuk Lymphoma,2007, 48(3): 570-576.